Sio Capital Management LLC Raises Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Sio Capital Management LLC raised its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 153.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,971,948 shares of the company's stock after purchasing an additional 1,193,024 shares during the quarter. Ventyx Biosciences accounts for about 1.7% of Sio Capital Management LLC's investment portfolio, making the stock its 18th biggest holding. Sio Capital Management LLC owned 2.79% of Ventyx Biosciences worth $4,299,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Palumbo Wealth Management LLC purchased a new stake in shares of Ventyx Biosciences during the third quarter valued at $26,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock valued at $30,000 after purchasing an additional 5,310 shares during the last quarter. SG Americas Securities LLC bought a new position in Ventyx Biosciences during the second quarter valued at approximately $32,000. Intech Investment Management LLC purchased a new stake in Ventyx Biosciences in the third quarter worth approximately $42,000. Finally, The Manufacturers Life Insurance Company grew its position in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock worth $56,000 after purchasing an additional 7,096 shares during the period. 97.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

VTYX has been the topic of a number of research reports. Oppenheimer restated an "outperform" rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. Wells Fargo & Company lowered their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating on the stock in a research note on Monday, August 12th. HC Wainwright reissued a "neutral" rating and set a $6.00 price objective on shares of Ventyx Biosciences in a research report on Monday, November 11th. Finally, Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Ventyx Biosciences Stock Up 1.1 %

NASDAQ:VTYX traded up $0.03 during trading hours on Friday, hitting $2.68. 728,728 shares of the stock traded hands, compared to its average volume of 2,052,684. The stock has a 50 day moving average price of $2.20 and a 200 day moving average price of $2.62. The company has a market cap of $189.50 million, a price-to-earnings ratio of -1.12 and a beta of 0.37. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48.

Insider Activity at Ventyx Biosciences

In other Ventyx Biosciences news, CEO Raju Mohan purchased 261,752 shares of the firm's stock in a transaction on Monday, November 25th. The shares were acquired at an average cost of $2.01 per share, with a total value of $526,121.52. Following the completion of the acquisition, the chief executive officer now directly owns 2,175,028 shares in the company, valued at $4,371,806.28. The trade was a 13.68 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 18.18% of the stock is owned by corporate insiders.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.